Bank of America Corp DE decreased its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 3.0% during the first quarter, Holdings Channel reports. The fund owned 43,143 shares of the biopharmaceutical company’s stock after selling 1,334 shares during the period. Bank of America Corp DE’s holdings in Agios Pharmaceuticals were worth $2,520,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in AGIO. Schwab Charles Investment Management Inc. raised its stake in shares of Agios Pharmaceuticals by 9.4% in the first quarter. Schwab Charles Investment Management Inc. now owns 83,327 shares of the biopharmaceutical company’s stock worth $4,867,000 after buying an additional 7,158 shares during the last quarter. BlackRock Inc. increased its position in shares of Agios Pharmaceuticals by 8,463.5% in the first quarter. BlackRock Inc. now owns 2,167,074 shares of the biopharmaceutical company’s stock worth $126,556,000 after buying an additional 2,141,768 shares during the period. Geode Capital Management LLC increased its position in shares of Agios Pharmaceuticals by 8.3% in the first quarter. Geode Capital Management LLC now owns 263,899 shares of the biopharmaceutical company’s stock worth $15,410,000 after buying an additional 20,336 shares during the period. Vanguard Group Inc. increased its position in shares of Agios Pharmaceuticals by 5.2% in the first quarter. Vanguard Group Inc. now owns 2,597,391 shares of the biopharmaceutical company’s stock worth $151,688,000 after buying an additional 129,159 shares during the period. Finally, Legal & General Group Plc increased its position in shares of Agios Pharmaceuticals by 209.2% in the first quarter. Legal & General Group Plc now owns 10,011 shares of the biopharmaceutical company’s stock worth $585,000 after buying an additional 6,773 shares during the period. 84.53% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Agios Pharmaceuticals, Inc. (AGIO) traded down 1.49% during midday trading on Thursday, reaching $59.66. The company’s stock had a trading volume of 41,016 shares. The company’s 50-day moving average price is $56.81 and its 200 day moving average price is $51.69. The company’s market capitalization is $2.88 billion. Agios Pharmaceuticals, Inc. has a 12-month low of $35.84 and a 12-month high of $67.74.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.57) by $0.21. Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 75.48%. The company had revenue of $11.30 million for the quarter, compared to the consensus estimate of $10.68 million. During the same period last year, the business earned ($1.47) EPS. The firm’s quarterly revenue was up 62.1% on a year-over-year basis. On average, equities research analysts forecast that Agios Pharmaceuticals, Inc. will post ($6.90) earnings per share for the current year.

WARNING: “Bank of America Corp DE Sells 1,334 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/08/10/bank-of-america-corp-de-sells-1334-shares-of-agios-pharmaceuticals-inc-nasdaqagio.html.

A number of equities analysts have recently issued reports on AGIO shares. Oppenheimer Holdings, Inc. set a $75.00 price objective on Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, June 11th. ValuEngine upgraded Agios Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Zacks Investment Research upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, April 28th. Canaccord Genuity set a $90.00 price objective on Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, May 18th. Finally, Cann restated a “buy” rating and set a $75.00 price objective on shares of Agios Pharmaceuticals in a research report on Wednesday, April 19th. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $71.56.

In related news, Director Lewis Clayton Jr. Cantley sold 2,036 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $47.10, for a total transaction of $95,895.60. Following the completion of the transaction, the director now owns 91,206 shares of the company’s stock, valued at approximately $4,295,802.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Scott Biller sold 4,292 shares of the firm’s stock in a transaction that occurred on Wednesday, June 21st. The shares were sold at an average price of $55.00, for a total value of $236,060.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 79,120 shares of company stock valued at $4,557,207. 10.55% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.